Is OLMA or TNGX more profitable?

Tango Therapeutics' return on equity of -41.54% beat Olema Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Olema Pharmaceuticals N/A -46.00% -41.22% Tango Therapeutics N/A -41.54% -33.44%

Does the media favor OLMA or TNGX?

In the previous week, Tango Therapeutics had 2 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 3 mentions for Tango Therapeutics and 1 mentions for Olema Pharmaceuticals. Tango Therapeutics' average media sentiment score of 0.41 beat Olema Pharmaceuticals' score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tango Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to NAMS or OLMA?

In the previous week, NewAmsterdam Pharma had 1 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 2 mentions for NewAmsterdam Pharma and 1 mentions for Olema Pharmaceuticals. NewAmsterdam Pharma's average media sentiment score of 0.67 beat Olema Pharmaceuticals' score of 0.00 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Olema Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is DNLI or OLMA more profitable?

Olema Pharmaceuticals' return on equity of -46.00% beat Denali Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Denali Therapeutics N/A -52.20% -43.86% Olema Pharmaceuticals N/A -46.00% -41.22%

Does the media refer more to DNLI or OLMA?

In the previous week, Denali Therapeutics had 2 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 3 mentions for Denali Therapeutics and 1 mentions for Olema Pharmaceuticals. Denali Therapeutics' average media sentiment score of 1.00 beat Olema Pharmaceuticals' score of 0.00 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Olema Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, TLX or OLMA?

Telix Pharmaceuticals has higher revenue and earnings than Olema Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.97 -$7.12M N/A N/A Olema Pharmaceuticals N/A N/A -$162.45M -$2.02 N/A

Is TLX or OLMA more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Olema Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Telix Pharmaceuticals N/A N/A N/A Olema Pharmaceuticals N/A -46.00% -41.22%

Does the media refer more to TLX or OLMA?

In the previous week, Telix Pharmaceuticals had 4 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 5 mentions for Telix Pharmaceuticals and 1 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 0.00 beat Telix Pharmaceuticals' score of -0.20 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Olema Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, GPCR or OLMA?

Structure Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Structure Therapeutics N/A N/A -$141.20M -$0.87 N/A Olema Pharmaceuticals N/A N/A -$162.45M -$2.02 N/A

Is GPCR or OLMA more profitable?

Structure Therapeutics' return on equity of -24.91% beat Olema Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Structure Therapeutics N/A -24.91% -23.67% Olema Pharmaceuticals N/A -46.00% -41.22%

Does the media prefer GPCR or OLMA?

In the previous week, Structure Therapeutics and Structure Therapeutics both had 1 articles in the media. Structure Therapeutics' average media sentiment score of 0.00 equaled Olema Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Olema Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Olema Pharmaceuticals (OLMA) Competitors

$12.28 +0.01 (+0.08%)

Closing price 07/9/2026 04:00 PM Eastern

Extended Trading

$12.30 +0.02 (+0.17%)

As of 04:09 AM Eastern

Compare

OLMA vs. TNGX, NAMS, DNLI, TLX, and GPCR

Should you buy Olema Pharmaceuticals stock or one of its competitors? MarketBeat compares Olema Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Olema Pharmaceuticals include Tango Therapeutics (TNGX), NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), Telix Pharmaceuticals (TLX), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry.

How does Olema Pharmaceuticals compare to Tango Therapeutics?

Olema Pharmaceuticals (NASDAQ:OLMA) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

Olema Pharmaceuticals has a beta of 2, meaning that its stock price is 100% more volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market.

Olema Pharmaceuticals currently has a consensus target price of $44.10, suggesting a potential upside of 259.12%. Tango Therapeutics has a consensus target price of $41.50, suggesting a potential upside of 35.98%. Given Olema Pharmaceuticals' higher possible upside, equities research analysts clearly believe Olema Pharmaceuticals is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

Tango Therapeutics' return on equity of -41.54% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Tango Therapeutics	N/A	-41.54%	-33.44%

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Tango Therapeutics had 2 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 3 mentions for Tango Therapeutics and 1 mentions for Olema Pharmaceuticals. Tango Therapeutics' average media sentiment score of 0.41 beat Olema Pharmaceuticals' score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tango Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tango Therapeutics has higher revenue and earnings than Olema Pharmaceuticals. Tango Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Tango Therapeutics	$56.99M	77.46	-$101.59M	-$0.83	N/A

Summary

Tango Therapeutics beats Olema Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Olema Pharmaceuticals (NASDAQ:OLMA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Olema Pharmaceuticals has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

In the previous week, NewAmsterdam Pharma had 1 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 2 mentions for NewAmsterdam Pharma and 1 mentions for Olema Pharmaceuticals. NewAmsterdam Pharma's average media sentiment score of 0.67 beat Olema Pharmaceuticals' score of 0.00 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Olema Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NewAmsterdam Pharma currently has a consensus target price of $49.00, suggesting a potential upside of 36.41%. Olema Pharmaceuticals has a consensus target price of $44.10, suggesting a potential upside of 259.12%. Given Olema Pharmaceuticals' higher probable upside, analysts clearly believe Olema Pharmaceuticals is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Olema Pharmaceuticals has lower revenue, but higher earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	186.62	-$203.82M	-$1.79	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 12.7% of NewAmsterdam Pharma shares are owned by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

NewAmsterdam Pharma has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2, suggesting that its share price is 100% more volatile than the broader market.

Summary

NewAmsterdam Pharma beats Olema Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Olema Pharmaceuticals (NASDAQ:OLMA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

Denali Therapeutics currently has a consensus price target of $34.25, suggesting a potential upside of 25.87%. Olema Pharmaceuticals has a consensus price target of $44.10, suggesting a potential upside of 259.12%. Given Olema Pharmaceuticals' higher possible upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 12.5% of Denali Therapeutics shares are held by company insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Olema Pharmaceuticals' return on equity of -46.00% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

In the previous week, Denali Therapeutics had 2 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 3 mentions for Denali Therapeutics and 1 mentions for Olema Pharmaceuticals. Denali Therapeutics' average media sentiment score of 1.00 beat Olema Pharmaceuticals' score of 0.00 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Olema Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Denali Therapeutics has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2, meaning that its share price is 100% more volatile than the broader market.

Olema Pharmaceuticals has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	13.07	-$512.54M	-$2.88	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

Summary

Olema Pharmaceuticals beats Denali Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Olema Pharmaceuticals (NASDAQ:OLMA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

In the previous week, Telix Pharmaceuticals had 4 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 5 mentions for Telix Pharmaceuticals and 1 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 0.00 beat Telix Pharmaceuticals' score of -0.20 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Olema Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Telix Pharmaceuticals' return on equity of 0.00% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

Telix Pharmaceuticals has a beta of -0.31, meaning that its share price is 131% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2, meaning that its share price is 100% more volatile than the broader market.

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Telix Pharmaceuticals has higher revenue and earnings than Olema Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.97	-$7.12M	N/A	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

Telix Pharmaceuticals presently has a consensus price target of $21.00, indicating a potential upside of 78.27%. Olema Pharmaceuticals has a consensus price target of $44.10, indicating a potential upside of 259.12%. Given Olema Pharmaceuticals' higher possible upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Telix Pharmaceuticals beats Olema Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Olema Pharmaceuticals (NASDAQ:OLMA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

Structure Therapeutics presently has a consensus price target of $110.55, indicating a potential upside of 100.48%. Olema Pharmaceuticals has a consensus price target of $44.10, indicating a potential upside of 259.12%. Given Olema Pharmaceuticals' higher possible upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Structure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Structure Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Structure Therapeutics and Structure Therapeutics both had 1 articles in the media. Structure Therapeutics' average media sentiment score of 0.00 equaled Olema Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Olema Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Structure Therapeutics' return on equity of -24.91% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

Structure Therapeutics has a beta of -1.5, meaning that its stock price is 250% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2, meaning that its stock price is 100% more volatile than the broader market.

Summary

Structure Therapeutics beats Olema Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

Get Olema Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OLMA vs. The Competition

Export

Metric	Olema Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.07B	$3.78B	$6.93B	$12.49B
Dividend Yield	N/A	2.18%	2.68%	7.79%
P/E Ratio	-6.08	21.70	27.37	24.61
Price / Sales	N/A	328.99	551.56	113.75
Price / Cash	N/A	145.39	48.45	59.17
Price / Book	2.09	8.62	11.02	6.46
Net Income	-$162.45M	$23.85M	$3.57B	$331.60M
7 Day Performance	-2.85%	0.96%	0.42%	0.33%
1 Month Performance	25.05%	13.39%	6.55%	2.51%
1 Year Performance	153.20%	55.25%	29.66%	21.59%

Olema Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OLMA Olema Pharmaceuticals	1.7986 of 5 stars	$12.28 +0.1%	$44.10 +259.1%	+146.1%	$1.07B	N/A	N/A	70
TNGX Tango Therapeutics	2.6712 of 5 stars	$29.75 -0.6%	$41.50 +39.5%	+405.3%	$4.30B	$56.99M	N/A	90
NAMS NewAmsterdam Pharma	3.0975 of 5 stars	$35.56 +1.9%	$49.00 +37.8%	+66.0%	$4.15B	$22.57M	N/A	4	Options Volume Gap Up
DNLI Denali Therapeutics	3.4911 of 5 stars	$26.20 +1.8%	$34.25 +30.7%	+81.4%	$4.15B	$330.53M	N/A	430	News Coverage Positive News
TLX Telix Pharmaceuticals	4.5527 of 5 stars	$11.72 -3.5%	$21.13 +80.2%	-30.4%	$3.98B	$803.79M	N/A	1,184	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OLMA) was last updated on 7/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Olema Pharmaceuticals (OLMA) Competitors

OLMA vs. TNGX, NAMS, DNLI, TLX, and GPCR

How does Olema Pharmaceuticals compare to Tango Therapeutics?

Summary

How does Olema Pharmaceuticals compare to NewAmsterdam Pharma?

Summary

How does Olema Pharmaceuticals compare to Denali Therapeutics?

Summary

How does Olema Pharmaceuticals compare to Telix Pharmaceuticals?

Summary

How does Olema Pharmaceuticals compare to Structure Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OLMA vs. The Competition

Olema Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Olema Pharmaceuticals (OLMA) Competitors

OLMA vs. TNGX, NAMS, DNLI, TLX, and GPCR

How does Olema Pharmaceuticals compare to Tango Therapeutics?

Which has more volatility & risk, OLMA or TNGX?

Do analysts prefer OLMA or TNGX?

Is OLMA or TNGX more profitable?

Do institutionals & insiders hold more shares of OLMA or TNGX?

Does the media favor OLMA or TNGX?

Which has higher valuation & earnings, OLMA or TNGX?

Summary

How does Olema Pharmaceuticals compare to NewAmsterdam Pharma?

Is NAMS or OLMA more profitable?

Does the media refer more to NAMS or OLMA?

Do analysts prefer NAMS or OLMA?

Which has better earnings and valuation, NAMS or OLMA?

Do institutionals and insiders have more ownership in NAMS or OLMA?

Which has more volatility and risk, NAMS or OLMA?

Summary

How does Olema Pharmaceuticals compare to Denali Therapeutics?

Do analysts recommend DNLI or OLMA?

Do insiders & institutionals hold more shares of DNLI or OLMA?

Is DNLI or OLMA more profitable?

Does the media refer more to DNLI or OLMA?

Which has more volatility and risk, DNLI or OLMA?

Which has higher valuation and earnings, DNLI or OLMA?

Summary

How does Olema Pharmaceuticals compare to Telix Pharmaceuticals?

Does the media refer more to TLX or OLMA?

Is TLX or OLMA more profitable?

Which has more volatility & risk, TLX or OLMA?

Do insiders and institutionals have more ownership in TLX or OLMA?

Which has stronger valuation and earnings, TLX or OLMA?

Do analysts recommend TLX or OLMA?

Summary

How does Olema Pharmaceuticals compare to Structure Therapeutics?

Do analysts recommend GPCR or OLMA?

Which has higher valuation & earnings, GPCR or OLMA?

Do institutionals and insiders have more ownership in GPCR or OLMA?

Does the media prefer GPCR or OLMA?

Is GPCR or OLMA more profitable?

Which has more risk & volatility, GPCR or OLMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OLMA vs. The Competition

Olema Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools